الفهرس 
List of ContentsOnly 14 pages are availabe for public view
 |  | from | 102 |  |  |
| | | from | 102 | | |
Abstract
Vascular calcification has been shown as a critical indicator of cardiovascular diseases and all-cause mortality in patients with chronic kidney disease, occurring 10–20 years earlier in chronic kidney disease patients when compared with the general population, and with incidence increasing with chronic kidney disease progression. Patients with chronic kidney disease and vascular calcification were suggested to be considered at the highest cardiovascular disease risk by the Kidney Disease The urrent study included 29 patients received a renal transplant at least 12 months ago (transplant group), 34 patients who diagnosed with ESKD and receiving regular haemodialysis (ESKD group) and 30 normal individuals as control group.This study showed the average sclerostin level in normal subjects, which was much higher in patients on dialysis, and levels decreased after transplantation, but did not reach the normal levels in many patients. Serum level of sclerostin had significant positive correlation with atherosclerosis in both dialysis and transplant patients. Moreover, sclerostin had a good diagnostic performance regarding vascular calcification.Sclerostin had negative significant correlation with glomerular filtration rate and serum calcium and positive significant correlation with serum phosphate, parathermone hormone and intima media thickness. Out of the transplant group; 9 (31%) patients had vascular calcification and 20 (69%) patients hadn’t vascular calcification. There were no significant differences between both groups among transplant subjects as regard sclerostinIn conclusion, sclerostin was higher in ESKD and renal transplant patients, but could not be used for earlydetectionofvascularcalcification.